RxDoctor Payments DataLook up a doctor →

Lynette Weitman Nicholson, PA

Medical · Pembroke Pines, FLNPI 1538378823

Payments from drug & device makers

$48,996in general payments, 2019–2025

Across 814 payments — averaging $60.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$20K
  • UCB, Inc.$14K
  • Johnson & Johnson$3K
  • Amgen$3K
  • AbbVie$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $6K from 27 others

What the payments were for

  • Consulting fees$7,02014%
  • Speaking & faculty fees$25,21551%
  • Travel & lodging$1,0472%
  • Food & beverage$15,60732%
  • Education$750%
  • Gifts$320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,996 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$12,945
Medicare patients
64
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept25$218,789
Cimzia (2 Pack)Certolizumab Pegol22$140,966
Cosentyx Sensoready (2 Pens)Secukinumab15$123,933
BenlystaBelimumab14$67,795
TymlosAbaloparatide16$41,762
ProliaDenosumab18$31,085
Hydroxychloroquine Sulfate186$7,540
MethotrexateMethotrexate Sodium236$5,417
Mycophenolate Mofetil22$3,183
Prednisone273$3,132
Celecoxib48$1,058
Duloxetine Hcl50$938
Methylprednisolone60$909
Pilocarpine Hcl11$906
Diclofenac Sodium19$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$14,102$140,96622 claims
GSKBenlysta$364$67,79514 claims
Radius Health, Inc.Tymlos$309$41,76216 claims
AmgenProlia$2,597$31,08518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →